Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Teijin Pharma, the core company of the Teijin Group's medical and pharmaceutical business, has launched Febuxostat in Korea.
Subscribe to our email newsletter
Febuxostat, a non-purine selective inhibitor of xanthine oxidase is used to treat chronic hyperuricemia in gout patients.
Teijin Pharma signed a licensing agreement with SK Chemicals in July 2004 for the development and marketing of Febuxostat in Korea, and as a licensee, SK Chemicals is marketing the Febuxostat under the brand name Feburic.
Takeda Pharmaceuticals North America and Takeda Canada who are also licensee have rights to market Febuxostat under the brand name Uloric.
Menarini Group will market the drug under the brand name Adenuric in Europe including France, the U.K., Germany, Ireland, Italy, Greece, Austria, Spain and Cyprus.